About Royal MobyRMSativa Hybrid
Shows almost pure sativa qualities when she grows and which gives a spectacularly powerful sativa effect when smoked. Her spectacular potency and effect, otherwise quite rare for a hybrid, and then her impressive size is what gave Royal Moby her name.
Spanish Bred, Dutch Genetics
Royal Moby is a very interesting strain. She is based on a unique Spanish sativa/indica hybrid that shows almost pure sativa qualities when she grows and which gives a spectacularly powerful sativa effect when smoked. Her spectacular potency and effect, otherwise quite rare for a hybrid, and then her impressive size is what gave Royal Moby her name. While playing around with genetics, some growers in Spain came across a Sativa/Indica hybrid which flowered to the full psychoactive effects of a pure Sativa.
Consuming Royal Moby is an incredible experience thanks to her very high THC content and potency. She delivers a mind-blowing psychedelic sativa effect and will have you suitably medicated in no-time.
Royal Moby is an excellent strain, and you should definitely check her out if you love powerful sativas and Hazes!
Description supplied by CannaConnection.
Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Lyphe Group Ltd
From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.
At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.lyphegroup.com